Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Somalogic stock price, quote, forecast and news

SLGC
US83444K1051
A3C14K

Price

2.10 USD
Today +/-
+0 USD
Today %
+0 %
P

Somalogic stock price

USD
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Somalogic stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Somalogic stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Somalogic stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Somalogic's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Somalogic Stock Price History

DateSomalogic Price
1/5/20242.10 USD
1/4/20242.20 USD

Somalogic Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Somalogic, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Somalogic from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Somalogic’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Somalogic. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Somalogic’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Somalogic’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Somalogic’s growth potential.

Somalogic Revenue, EBIT and net profit per share

DateSomalogic RevenueSomalogic EBITSomalogic Net Income
2029e245.51 M USD0 USD-51.96 M USD
2028e205.33 M USD-94.86 M USD-73.13 M USD
2027e170.24 M USD-108.43 M USD-88.53 M USD
2026e143.16 M USD-71.35 M USD-100.08 M USD
2025e120.84 M USD-96.63 M USD-95.59 M USD
2024e100.6 M USD-111.05 M USD-102.48 M USD
2023e85.48 M USD-132.6 M USD-114.03 M USD
202297.67 M USD-175.76 M USD-109.16 M USD
202181.63 M USD-73.31 M USD-87.55 M USD
202055.89 M USD-34.23 M USD-53.02 M USD
201932.19 M USD-50.95 M USD-57 M USD

Somalogic Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M USD)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M USD)EBIT (M USD)EBIT MARGIN (%)NET INCOME (M USD)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20192020202120222023e2024e2025e2026e2027e2028e2029e
3255819785100120143170205245
-71.8847.2719.75-12.3717.6520.0019.1718.8820.5919.51
43.7560.0059.2655.67-------
143348540000000
-50-34-73-175-132-111-96-71-108-940
-156.25-61.82-90.12-180.41-155.29-111.00-80.00-49.65-63.53-45.85-
-57-53-87-109-114-102-95-100-88-73-51
--7.0264.1525.294.59-10.53-6.865.26-12.00-17.05-30.14
181.16181.16181.55183.990000000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Somalogic Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Somalogic is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M USD)RECEIVABLES (M USD)OTHER REC. (M USD)INVENTORIES (M USD)OTHER CURRENT LIAB. (M USD)CURRENT ASSETS (M USD)TANGIBLE ASSETS (M USD)LONG-T. INVEST. (M USD)LONG-T. REC. (M USD)INTANGIBLE ASSETS (M USD)GOODWILL (M USD)OTHER NON-CURRENT ASSETS (M USD)NON-CURRENT ASSETS (M USD)TOTAL ASSETS (M USD)LIABILITIESCOMMON STOCK (M USD)ADDITIONAL PAID-IN CAPITAL (B USD)RETAINED EARNINGS (M USD)OTHER EQUITY (M USD)UNREAL. GAINS/LOSSES (M USD)EQUITY (M USD)LIABILITIES (M USD)PROVISIONS (M USD)OTHER SHORT-TERM LIAB. (M USD)SHORT-TERM DEBTS (M USD)LONG-TERM DEBT PORTION (M USD)SHORT-TERM REC. (M USD)LONG-T. LIAB. (M USD)DEFERRED TAXES (M USD)OTHER LIAB. (M USD)LONG-T. LIABILITIES (M USD)DEBT (M USD)TOTAL CAPITAL (M USD)
2019202020212022
       
45.6204.9657.7539.6
4.217.417.117
0000
8.4711.213.9
1.62.75.611.2
59.8232691.6581.7
5.73.99.619.6
0000
0009.3
00016.7
00010.4
5.86.459.7
11.510.314.665.7
71.3242.3706.2647.4
       
0.7202.800
0.380.391.111.17
-358.4-411.4-498.9-608.1
00-0.1-0.5
0000
20.7186.2612562.5
37.115.116.8
4.86.311.120.7
1.123.15.9
0000
02.400
8.917.829.343.4
36.634.300
0000
5.44.364.841.5
4238.664.841.5
50.956.494.184.9
71.6242.6706.1647.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Somalogic provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Somalogic's financial health and stability.

Assets

Somalogic's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Somalogic must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Somalogic after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Somalogic's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M USD)DEPRECIATION (M USD)DEFERRED TAXES (M USD)CHANGES IN WORKING CAPITAL (M USD)NON-CASH ITEM (M USD)PAID INTEREST (M USD)PAID TAXES (M USD)NET CASH FLOW FROM OPERATING ACTIVITIES (M USD)CAPITAL EXPENDITURES (M USD)CASH FLOW FROM INVESTING ACTIVITIES (M USD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M USD)INTEREST INCOME AND EXPENSES (M USD)NET DEBT CHANGE (M USD)NET CHANGE IN EQUITY (M USD)CASH FLOW FROM FINANCING ACTIVITIES (M USD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M USD)TOTAL DIVIDENDS PAID (M USD)NET CHANGE IN CASH FLOW (M USD)FREE CASH FLOW (M USD)SHARE-BASED COMPENSATION (M USD)
2019202020212022
-57-53-87-109
3224
0000
-14-8427
17457120
3310
0000
-50-28-36-100
0-1-6-5
30-9-18582
31-8-17887
0000
03-360
018035
01884975
055300
0000
-19150275-12
-51.22-29.5-43.7-105.89
0000

Somalogic stock margins

The Somalogic margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Somalogic. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Somalogic.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Somalogic's sales revenue. A higher gross margin percentage indicates that the Somalogic retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Somalogic's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Somalogic's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Somalogic's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Somalogic. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Somalogic's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Somalogic Margin History

Somalogic Gross marginSomalogic Profit marginSomalogic EBIT marginSomalogic Profit margin
2029e55.6 %0 %-21.17 %
2028e55.6 %-46.2 %-35.62 %
2027e55.6 %-63.69 %-52 %
2026e55.6 %-49.84 %-69.9 %
2025e55.6 %-79.96 %-79.1 %
2024e55.6 %-110.39 %-101.87 %
2023e55.6 %-155.13 %-133.4 %
202255.6 %-179.95 %-111.76 %
202159 %-89.81 %-107.25 %
202059.64 %-61.25 %-94.86 %
201943.99 %-158.28 %-177.07 %

Somalogic Stock Sales Revenue, EBIT, Earnings per Share

The Somalogic earnings per share therefore indicates how much revenue Somalogic has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Somalogic earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Somalogic's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Somalogic’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Somalogic's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Somalogic Revenue, EBIT and net profit per share

DateSomalogic Sales per ShareSomalogic EBIT per shareSomalogic Earnings per Share
2029e1.3 USD0 USD-0.28 USD
2028e1.09 USD0 USD-0.39 USD
2027e0.9 USD0 USD-0.47 USD
2026e0.76 USD0 USD-0.53 USD
2025e0.64 USD0 USD-0.51 USD
2024e0.53 USD0 USD-0.54 USD
2023e0.45 USD0 USD-0.6 USD
20220.53 USD-0.96 USD-0.59 USD
20210.45 USD-0.4 USD-0.48 USD
20200.31 USD-0.19 USD-0.29 USD
20190.18 USD-0.28 USD-0.31 USD

Somalogic business model

SomaLogic Inc is a diagnostic biotech company specializing in a new way of clinically diagnosing diseases. It was founded in 2000 by Larry Gold, a renowned researcher and pioneer in the field of molecular diagnostics. The idea behind Somalogic arose from the need to bridge the gap between clinical needs and conventional diagnostic methods. SomaLogic's business model can be described as a service provider and licensee. The company offers its customers a wide range of products and services, from technology development to clinical disease diagnosis. The model is based on Somalogic's unique ability to measure a large number of proteins simultaneously, thus creating a comprehensive picture of their biological activity. The spheres of Somalogic encompass three main areas: proteins, data, and biomedicine. The protein sphere refers to Somalogic's core competence in the field of proteomics. The company has developed a proprietary technology that allows for the measurement of up to 5000 proteins in a single sample. Somalogic's technology is based on a special sample format called "SOMAScan," which utilizes proprietary aptamer technology to achieve ultra-high protein molecular signature accuracy. Somalogic's data sphere is deeply rooted in both the protein sphere and the biomedicine sphere. The company has a proprietary database that encompasses thousands of proteins. This database is continuously updated and expanded to provide increasingly robust quantitative protein data. The database enables Somalogic to identify and validate specific protein signatures associated with diseases. Somalogic also utilizes machine learning and artificial intelligence tools to take the interpretation of this data to the next level. The biomedicine sphere of Somalogic is the area where the company brings its diagnostic and therapeutic developments to the market. Somalogic works closely with pharmaceutical companies and clinical laboratories to develop clinical diagnostic tests based on its proprietary technology. The company has generated valid clinical data on a range of diseases and demonstrated the ability to identify biomarkers specifically associated with certain diseases. In its business development, Somalogic has created and licensed a wide range of products. The company has successfully formed partnerships with a number of companies and institutions to provide both proteomics tools and services. Some notable examples include partnerships such as collaboration with Biogen in the development of diagnostic tools for multiple sclerosis and other neurological disorders. Another example of Somalogic's product range is the successful collaboration with the New York State Health Department, where the company used its technology to investigate the SARS-CoV-2 virus. In this context, Somalogic generated information about specific biomarkers for COVID-19 and other masked and bound viral diseases. SomaLogic has the potential to change the way diseases are diagnosed and therapeutically treated. The company is on a path to revolutionize the diagnostic capabilities of the healthcare system and leave its mark on the healthcare market. Somalogic is one of the most popular companies on Eulerpool.com.

Somalogic SWOT Analysis

Strengths

Somalogic Inc is known for its cutting-edge technology and expertise in the field of proteomics. The company has developed innovative platforms and tools that enable the measurement of thousands of proteins simultaneously, providing valuable insights for biomedical research and drug discovery.

Somalogic Inc holds a robust intellectual property portfolio, encompassing various patents and proprietary technologies. This not only gives the company a competitive advantage but also serves as a barrier to entry for potential rivals in the market.

Weaknesses

While Somalogic Inc is a recognized leader in proteomics, its market presence is not as widespread compared to some larger competitors. The company may need to invest in marketing and business development initiatives to expand its customer base and increase market share.

Somalogic Inc heavily relies on research funding from academic institutions, government agencies, and pharmaceutical companies. Any decline or interruption in funding sources could pose a risk to the company's financial stability and ongoing research projects.

Opportunities

The field of precision medicine is rapidly evolving, and Somalogic Inc has the opportunity to leverage its advanced proteomic technologies to contribute to personalized diagnostics and treatment approaches. By partnering with healthcare providers and pharmaceutical companies, the company can tap into this growing market segment.

Somalogic Inc can explore opportunities to expand its operations and establish collaborations in international markets. By entering new geographic regions, the company can gain access to a larger customer base, diverse research projects, and potentially untapped sources of funding.

Threats

The market for proteomic technologies is highly competitive, with numerous players offering similar solutions. Somalogic Inc faces the constant challenge of staying ahead of competitors, both in terms of technology advancements and pricing strategies.

The healthcare and biotechnology sectors are subject to strict regulations and compliance requirements. Somalogic Inc must stay updated on regulatory changes and ensure its operations and products meet all necessary standards. Non-compliance could lead to legal issues, reputational damage, and loss of market trust.

Somalogic Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Somalogic historical P/E ratio, EBIT, and P/S ratio.

Somalogic shares outstanding

The number of shares was Somalogic in 2023 — This indicates how many shares 183.99 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Somalogic earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Somalogic's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Somalogic’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Somalogic's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Somalogic Stock splits

In Somalogic's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Somalogic.

Somalogic latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.17 USD-0.12 USD (30.8 %)2023 Q3
6/30/2023-0.16 USD-0.13 USD (17.77 %)2023 Q2
3/31/2023-0.21 USD-0.18 USD (12.88 %)2023 Q1
12/31/2022-0.21 USD-0.26 USD (-21.38 %)2022 Q4
9/30/2022-0.2 USD-0.18 USD (10.27 %)2022 Q3
6/30/2022-0.18 USD-0.13 USD (27.86 %)2022 Q2
3/31/2022-0.16 USD-0.02 USD (87.55 %)2022 Q1
12/31/2021-0.13 USD-0.13 USD (0.08 %)2021 Q4
1

Somalogic list of shareholders

%
Name
Stocks
Change
Date
6.88096 % ARK Investment Management LLC12,983,002288,7779/30/2023
6.68024 % Casdin Capital, LLC12,604,275-3,4306/30/2023
5.49467 % Novartis AG10,367,34004/10/2023
5.02022 % BlackRock Institutional Trust Company, N.A.9,472,149243,5276/30/2023
4.63294 % Nikko Asset Management Co., Ltd.8,741,4374,411,2486/30/2023
4.13788 % The Vanguard Group, Inc.7,807,350102,3426/30/2023
3.95866 % Madryn Asset Management, LP7,469,20206/30/2023
2.76433 % Tikvah Management LLC5,215,7401,001,0006/30/2023
2.75547 % Millennium Management LLC5,199,020-621,9176/30/2023
2.60043 % Point72 Asset Management, L.P.4,906,49045,4276/30/2023
1
2
3
4
5
...
10

Somalogic Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Illumina Stock
Illumina
SupplierCustomer0,930,940,840,790,73-
Danaher Stock
Danaher
SupplierCustomer0,920,830,730,840,59-
Twist Bioscience Stock
Twist Bioscience
SupplierCustomer0,910,230,850,950,91-
Agilent Technologies Stock
Agilent Technologies
SupplierCustomer0,900,580,850,920,78-
NEC Stock
NEC
SupplierCustomer0,390,16-0,290,380,61-
Novo Nordisk B Stock
Novo Nordisk B
SupplierCustomer-0,400,51-0,53-0,39-0,52-
Novartis Stock
Novartis
SupplierCustomer-0,510,44-0,77-0,81-0,34-
1

Most common questions regarding Somalogic

What values and corporate philosophy does Somalogic represent?

Somalogic Inc represents a set of core values and a corporate philosophy that aligns with its mission. The company is committed to excellence and innovation in the field of protein biomarker discovery. With a focus on transforming healthcare through the power of proteomics, Somalogic Inc strives to develop groundbreaking solutions for early disease detection, personalized medicine, and improved patient outcomes. By leveraging its proprietary SomaScan® Platform, the company aims to provide advanced insights into human health and empower individuals to live longer and healthier lives.

In which countries and regions is Somalogic primarily present?

Somalogic Inc is primarily present in the United States.

What significant milestones has the company Somalogic achieved?

Some significant milestones achieved by Somalogic Inc include pioneering the development of a proprietary proteomics technology called SomaScan, which enables the measurement of thousands of proteins in a single blood sample. The company has also successfully partnered with leading pharmaceutical and biotechnology companies to advance precision medicine and biomarker discovery efforts. In addition, Somalogic Inc has received numerous accolades and recognition for its innovative scientific advancements and contributions to the field of proteomics.

What is the history and background of the company Somalogic?

Somalogic Inc is a leading biotechnology company specializing in proteomics and molecular diagnostics. Founded in 2000, the company has a rich history of innovation in developing powerful tools to measure proteins. Somalogic's proprietary technology, known as SomaScan®, enables rapid and accurate protein analysis for various applications, including drug discovery, diagnostics, and personalized medicine. With a diverse and talented team of scientists and engineers, Somalogic has forged numerous partnerships with pharmaceutical companies and research institutions to further advance the field of proteomics. Leveraging its expertise and cutting-edge technology, Somalogic Inc continues to make significant contributions to the understanding and treatment of various diseases.

Who are the main competitors of Somalogic in the market?

The main competitors of Somalogic Inc in the market include companies such as Protagen AG, Biodesix Inc, and Myriad Genetics Inc. These companies operate in the same industry and offer similar products and services as Somalogic Inc. However, Somalogic Inc differentiates itself through its proprietary proteomics technology and innovative solutions. By providing unique and high-quality protein biomarker assays, Somalogic Inc remains positioned as a leading player in the market, enhancing diagnostic and research capabilities for their customers.

In which industries is Somalogic primarily active?

Somalogic Inc is primarily active in the healthcare and biotechnology industries.

What is the business model of Somalogic?

The business model of Somalogic Inc is focused on developing and commercializing precision health tools. They utilize their proprietary SomaScan® technology platform to analyze and measure proteins in the human body. By offering high-quality protein measurement solutions, Somalogic Inc enables advancements in biopharmaceutical research, clinical diagnostics, and personalized medicine. Their innovative approach provides valuable insights into disease detection, monitoring, and therapeutic development. Somalogic Inc's business model aims to revolutionize healthcare by delivering accurate and comprehensive protein data, leading to improved patient outcomes and advancements in the field of precision medicine.

What is the P/E ratio of Somalogic 2024?

The Somalogic P/E ratio is -3.77.

What is the P/S ratio of Somalogic 2024?

The Somalogic P/S ratio is 3.84.

What is the AlleAktien quality score of Somalogic?

The AlleAktien quality score for Somalogic is 3/10.

What is the revenue of Somalogic 2024?

The expected Somalogic revenue is 100.6 M USD.

How high is the profit of Somalogic 2024?

The expected Somalogic profit is -102.48 M USD.

What is the business model of Somalogic

Somalogic Inc is a company specializing in the development and distribution of innovative diagnostic and research products. It was founded in 2000 and is headquartered in Boulder, Colorado. The basic principle of Somalogic Inc is based on the ability to detect and analyze diseases and health conditions through specific molecules in the blood. To do this, the company has developed a unique technology based on the use of special aptamers. Aptamers are short DNA or RNA molecules that can specifically bind to certain proteins. Somalogic has built an extensive library of over 10 trillion aptamers capable of binding to almost all major proteins in the human body. Using these aptamers, Somalogic researchers can analyze more than 5,000 different proteins simultaneously with just a single drop of blood. One of Somalogic's key products is its diagnostic tests. These tests are used to diagnose various diseases or determine the risk for certain health conditions. For example, the company offers tests that can predict the risk of heart disease, cancer, or neurological disorders. Another important part of Somalogic is research and development. The company works closely with various research institutions to gain new insights into the functioning of the human body and potential treatment options. Somalogic relies on close collaboration with its customers and partners to provide tailored solutions and products. In summary, Somalogic Inc is an innovative company that uses state-of-the-art technologies and scientific knowledge to improve global health. The company offers a wide range of products and services that are of great importance for both diagnostics and research and development. Thanks to its unique technology and close collaboration with leading research institutions, Somalogic has already achieved numerous successes. And in the future, the company will continue to play an important role in the medical and healthcare industry.

What is the Somalogic dividend?

Somalogic pays a dividend of 0 USD distributed over payouts per year.

How often does Somalogic pay dividends?

The dividend cannot currently be calculated for Somalogic or the company does not pay out a dividend.

What is the Somalogic ISIN?

The ISIN of Somalogic is US83444K1051.

What is the Somalogic WKN?

The WKN of Somalogic is A3C14K.

What is the Somalogic ticker?

The ticker of Somalogic is SLGC.

How much dividend does Somalogic pay?

Over the past 12 months, Somalogic paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Somalogic is expected to pay a dividend of 0 USD.

What is the dividend yield of Somalogic?

The current dividend yield of Somalogic is .

When does Somalogic pay dividends?

Somalogic pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Somalogic?

Somalogic paid dividends every year for the past 0 years.

What is the dividend of Somalogic?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Somalogic located?

Somalogic is assigned to the 'Health' sector.

Wann musste ich die Aktien von Somalogic kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Somalogic from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Somalogic pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Somalogic in the year 2023?

In the year 2023, Somalogic distributed 0 USD as dividends.

In which currency does Somalogic pay out the dividend?

The dividends of Somalogic are distributed in USD.

All fundamentals about Somalogic

Our stock analysis for Somalogic Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Somalogic Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.